MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy

PRIMARY OBJECTIVES:

I. To design an automated MRI hardware/software platform for measuring and reporting left
ventricular (LV) function (volumes, strain, and ejection fraction [EF]), T1 myocardial
signal, and aortic pulse wave velocity (PWV).

II. To determine if pre- to 3 month post-anthracycline-based chemotherapy (Anth-bC) changes
in our MRI platform generated measures of LV volumes, EF, strain, myocardial T1, and aortic
PWV predict pre- to 24 month post-Anth-bC differences in these same parameters.

OUTLINE:

Patients undergo MRI scans for LV function, T1 myocardial signal, and aortic PWV at baseline,
3 months, and 24 months.

Inclusion Criteria:

- Receiving >= 350 mg/m^2 of Anth-bC therapy, or a combination of Anth-bC (>= 250
mg/m^2) and subsequent paclitaxel or Herceptin

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Intracranial metal, pacemakers, defibrillators, functioning neurostimulator devices,
or other implanted electronic devices

- Ferromagnetic cerebral aneurysm clips, or other intraorbital/intracranial metal

- Allergy to gadolinium or other severe drug allergies

- Unstable angina

- Significant ventricular arrhythmias (> 20 premature ventricular contractions
[PVCs]/minute due to gating difficulty)

- Acute myocardial infarction within 28 days

- Atrial fibrillation with uncontrolled ventricular response

- Moderate or severe aortic stenosis

- Claustrophobia

- Congestive heart failure (New York Heart Association [NYHA] class III or IV)

- Significant valvular disease, or significant pulmonary disease requiring supplemental
oxygen therapy

- Participants unwilling to complete the protocol (24 month duration)

- Women who are pregnant

- Patients unable or unwilling to provide informed consent